Literature Citations
1. Bis-(Imidazole/Benzimidazole)-pyridine Derivatives: Synthesis, Structure and Antimycobacterial Activity. Antoci, V., D. Cucu, G. Zbancioc, C. Moldoveanu, V. Mangalagiu, D. Amariucai-Mantu, A. Aricu, and Mangalagiu, II. Future Medicinal Chemistry, 2020. 12(3): p. 207-222. PMID[31916456].
[PubMed]. TB_02_2020.
2. Discovery of Hydrazone Containing Thiadiazoles as Mycobacterium tuberculosis Growth and Enoyl Acyl Carrier Protein Reductase (InhA) Inhibitors. Dogan, H., S.D. Dogan, M.G. Gunduz, V.S. Krishna, C. Lherbet, D. Sriram, O. Sahin, and E. Saripinar. European Journal of Medicinal Chemistry, 2020. 188: 112035. PMID[31951850].
[PubMed]. TB_02_2020.
3. Trehalose Synthesis Inhibitor: A Molecular in Silico Drug Design. Goncalves, L.M., E.T.V. Trevisol, B. de Azevedo Abrahim Vieira, and J.F. De Mesquita. Journal of Cellular Biochemistry, 2020. 121(2): p. 1114-1125. PMID[31478225].
[PubMed]. TB_02_2020.
4. Synthesis and Structure-activity Relationship Studies of C2-modified Analogs of the Antimycobacterial Natural Product Pyridomycin. Kienle, M., P. Eisenring, B. Stoessel, O.P. Horlacher, S. Hasler, G. van Colen, R.C. Hartkoorn, A. Vocat, S.T. Cole, and K.H. Altmann. Journal of Medicinal Chemistry, 2020. 63(3): p. 1105-1131. PMID[31904960].
[PubMed]. TB_02_2020.
5. 4-Substituted picolinohydrazonamides as a New Class of Potential Antitubercular Agents. Krause, M., H. Foks, D. Ziembicka, E. Augustynowicz-Kopec, A. Glogowska, I. Korona-Glowniak, K. Bojanowski, D. Siluk, and K. Gobis. European Journal of Medicinal Chemistry, 2020. 190: 112106. PMID[32061963].
[PubMed]. TB_02_2020.
6. Application of 2,4-bis(Halomethyl)quinoline: Synthesis and Biological Activities of 2,4-Bis(Benzofuran-2-yl)- and 2,4-Bis(Aroxymethyl)quinolines. Li, Y., Q. Xu, Z. Li, W. Gao, and Y. Chen. Molecular Diversity, 2020. 24(1): p. 167-178. PMID[30895448].
[PubMed]. TB_02_2020.
7. In Vitro Evaluation of the Inhibitory Effect of 3,5-Dichloro-2-pyridone on Mycobacterium tuberculosis H37Rv. Lin Ling, C.L., Hua Wu. Tropical Journal of Pharmaceutical Research, 2020. 19(1): p. 163-168.
[WOS]. TB_02_2020.
8. Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach. Liu, Y., Y. Tan, M.M. Islam, Y. Cao, X. Lu, S. Zeng, H.M.A. Hameed, P. Zhou, X. Cai, S. Wang, J.N. Mugweru, G. Zhang, H. Yin, J. Liu, E. Nuermberger, and T. Zhang. Antimicrobial Agents and Chemotherapy, 2020. 64(3). PMID[31843996]. PMCID [PMC7038284].
[PubMed]. TB_02_2020.
9. New 2-Ethylthio-4-methylaminoquinazoline Derivatives Inhibiting Two Subunits of Cytochrome bc1 in Mycobacterium tuberculosis. Lupien, A., C.S. Foo, S. Savina, A. Vocat, J. Piton, N. Monakhova, A. Benjak, D.A. Lamprecht, A.J.C. Steyn, K. Pethe, V.A. Makarov, and S.T. Cole. Plos Pathogens, 2020. 16(1): e1008270. PMID[31971990]. PMCID[PMC6999911].
[PubMed]. TB_02_2020.
10. Synthesis and Antibacterial Activity of Difluoromethyl cinnamoyl amides. Martinez, M.D., D.A. Riva, C. Garcia, F.J. Duran, and G. Burton. Molecules, 2020. 25(4): e789. PMID[32059479].
[PubMed]. TB_02_2020.
11. Allosteric Inhibitors of Mycobacterium tuberculosis Tryptophan synthase. Michalska, K., C. Chang, N.I. Maltseva, R. Jedrzejczak, G.T. Robertson, F. Gusovsky, P. McCarren, S.L. Schreiber, P.P. Nag, and A. Joachimiak. Protein Science, 2020. 29(3): p. 779-788. PMID[31930594]. PMCID [PMC7020977].
[PubMed]. TB_02_2020.
12. Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus. Raynaud, C., W. Daher, M.D. Johansen, F. Roquet-Baneres, M. Blaise, O.K. Onajole, A.P. Kozikowski, J.L. Herrmann, J. Dziadek, K. Gobis, and L. Kremer. ACS Infectious Diseases, 2020. 6(2): p. 324-337. PMID[31860799].
[PubMed]. TB_02_2020.
13. Mycobacterium tuberculosis Thymidylate synthase (ThyX) Is a Target for Plumbagin, a Natural Product with Antimycobacterial Activity. Sarkar, A., S. Ghosh, R. Shaw, M.M. Patra, F. Calcuttawala, N. Mukherjee, and S.K. Das Gupta. Plos One, 2020. 15(2): e0228657. PMID[32017790]. PMCID[PMC6999906].
[PubMed]. TB_02_2020.
14. Identification of Novel Selective Mtb-DHFR Inhibitors as Antitubercular Agents through Structure-based Computational Techniques. Sharma, K., N. Neshat, S. Sharma, N. Giri, A. Srivastava, F. Almalki, K. Saifullah, M.M. Alam, M. Shaquiquzzaman, and M. Akhter. Archiv der Pharmazie, 2020. 353(2): e1900287. PMID[31867798].
[PubMed]. TB_02_2020.
15. Novel Benzimidazole-Acrylonitrile Hybrids and Their Derivatives: Design, Synthesis and Antimycobacterial Activity. Sirim, M.M., V.S. Krishna, D. Sriram, and O. Unsal Tan. European Journal of Medicinal Chemistry, 2020. 188: e112010. PMID[31893548].
[PubMed]. TB_02_2020.
16. Synthesis and Antimycobacterial Activity of Thiazolidine-2,4-dione Based Derivatives with Halogenbenzohydrazones and Pyridinecarbohydrazones Substituents. Trotsko, N., J. Golus, P. Kazimierczak, A. Paneth, A. Przekora, G. Ginalska, and M. Wujec. European Journal of Medicinal Chemistry, 2020. 189: e112045. PMID[31951961].
[PubMed]. TB_02_2020.
17. Development of 1,2,4-Triazole-5-thione Derivatives as Potential Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) in Tuberculosis. Vora, D. Iranian Journal of Pharmaceutical Research, 2019. 18(4): p. 1742-1758.
[WOS]. TB_02_2020.
18. Antitubercular Triazines: Optimization and Intrabacterial Metabolism. Wang, X., D. Inoyama, R. Russo, S.G. Li, R. Jadhav, T.P. Stratton, N. Mittal, J.A. Bilotta, E. Singleton, T. Kim, S.D. Paget, R.S. Pottorf, Y.M. Ahn, A. Davila-Pagan, S. Kandasamy, C. Grady, S. Hussain, P. Soteropoulos, M.D. Zimmerman, H.P. Ho, S. Park, V. Dartois, S. Ekins, N. Connell, P. Kumar, and J.S. Freundlich. Cell Chemical Biology, 2020. 27(2): p. 172-185. PMID[31711854]. PMCID[PMC7035970].
[PubMed]. TB_02_2020.
19. Design, Synthesis, and Biological Evaluation of Novel 4H-Chromen-4-one Derivatives as Antituberculosis Agents against Multidrug-resistant Tuberculosis. Zhao, W., B. Wang, Y. Liu, L. Fu, L. Sheng, H. Zhao, Y. Lu, and D. Zhang. European Journal of Medicinal Chemistry, 2020. 189: e112075. PMID[31986405].
[PubMed]. TB_02_2020.
Patent Citations
This month, no relevant Mycobacterium patents were identified.